Table 4.
Univariate and multivariate analysis of FEN1 associated with OS and RFS in TCGA HCC cohort.
| Univariate analysis | Multivariate analysis | |||||||
|---|---|---|---|---|---|---|---|---|
| OS (%) | HR | 95% CI | P value | HR | 95% CI | P value | ||
| Univariate and multivariate analyses of overall survival in HCC patients (n = 328) | ||||||||
| Age | <Medium (n = 161) | 116 (72.1%) | 0.822 | 0.580–1.165 | 0.270 | |||
| ≥Medium (n = 167) | 112(67.1%) | |||||||
| Gender | Female (n = 105) | 67 (63.8%) | 1.117 | 0.936-1.334 | 0.220 | |||
| Male (n = 223) | 161(72.2%) | |||||||
| Race | Others (n = 169) | 122 (72.2%) | 1.454 | 0.800-2.642 | 0.220 | |||
| White (n = 159) | 106 (66.7%) | |||||||
| TNM stage | Stage I/II (n = 245) | 187 (76.3%) | 2.483 | 1.713-3.600 | <0.001 | 2.271 | 1.544-3.339 | <0.001 |
| Stage III/IV (n = 83) | 41 (49.4%) | |||||||
| AFP expression | Low (n = 157) | 115 (73.3%) | 0.859 | 0.608-1.215 | 0.391 | |||
| High (n = 171) | 113 (66.1%) | |||||||
| FEN1 expression | Low (n = 163) | 124 (76.1%) | 1.606 | 1.133-2.277 | 0.008 | 1.378 | 0.935-2.029 | 0.105 |
| High (n = 165) | 104 (63.0%) | |||||||
|
| ||||||||
| Univariate and multivariate analyses of relapse-free survival in HCC patients (n = 328) | ||||||||
| Age | <Medium (n = 161) | 116 (72.1%) | 0.965 | 0.845-1.102 | 0.601 | |||
| ≥Medium (n = 167) | 112 (67.1%) | |||||||
| Gender | Female (n = 105) | 67 (63.8%) | 1.053 | 0.916-1.209 | 0.468 | |||
| Male (n = 223) | 161(72.2%) | |||||||
| Race | Others (n = 169) | 122 (72.2%) | 0.865 | 0.638-1.174 | 0.352 | |||
| White (n = 159) | 106 (66.7%) | |||||||
| TNM stage | Stage I/II (n = 245) | 187 (76.3%) | 2.066 | 1.538-2.775 | <0.001 | 1.883 | 1.388-2.556 | <0.001 |
| Stage III/IV (n = 83) | 41 (49.4%) | |||||||
| AFP expression | Low (n = 157) | 115 (73.3%) | 0.846 | 0.650-1.102 | 0.215 | |||
| High (n = 171) | 113 (66.1%) | |||||||
| FEN1 expression | Low (n = 163) | 124 (76.1%) | 1.593 | 1.221-2.078 | 0.001 | 1.387 | 1.043-1.845 | 0.025 |
| High (n = 165) | 104 (63.0%) | |||||||